Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy,
and radiation) as a potential new treatment for bile duct cancer that cannot be removed with
surgery.
The specific names of the interventions that will be used are:
- Y-90 (a type of radiation microsphere bead)
- Durvalumab (a type of immunotherapy)
- Gemcitabine (a type of chemotherapy)
- Cisplatin (a type of chemotherapy)